Research Article
c-kit and bcl-2 Are Not Useful Markers in Differentiating Adenoid Cystic Carcinoma from Polymorphous Low-Grade Adenocarcinoma
Table 2
Total immunoreactivity of bcl-2 and c-kit observed in ACC and PLGA expressed as number of cases () and as a percentage (%).
| | Total n of cases | ACC | PLGA | | 29 | 23 |
| | % immunostaining | <30 | 30–60 | >60 | <30 | 30–60 | >60% | | % | | % | | % | | % | | % | | % |
| | bcl-2 | 6 | 20.7 | 2 | 6.9 | 21 | 72.4 | 4 | 17.4 | 6 | 26.1 | 13 | 56.5 | | c-kit polyclonal | 13 | 44.8 | 8 | 27.6 | 8 | 27.6 | 19 | 82.6 | 2 | 8.7 | 2 | 8.7 | | c-kit monoclonal (pilot study) | 26 | 89.7 | 1 | 3.4 | 2 | 6.9 | 22 | 95.7 | 0 | 0 | 1 | 4.3 |
|
|
